EUCTR2018-000058-22-IT进行中（未招募）1 期
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors - ooo
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
- •- Available tumor tissue for biomarker analysis
- •- Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 166
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •- Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease
- •- Participants with a history of interstitial lung disease (ILD) / pneumonitis
- •- Prior malignancy active within the previous 3 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer
研究者
相似试验
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced Malignant TumorsMedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864EUCTR2018-000058-22-ESBristol-Myers Squibb International Corporation184
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced Malignant TumorsMedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864EUCTR2018-000058-22-GBBristol-Myers Squibb International Corporation184
招募中
1 期
An Investigational Study of Immunotherapy Combinations in ParticipantsWith Solid Cancers That Are Advanced or Have SpreadCTIS2023-508207-21-00Bristol Myers Squibb International Corporation325
已完成
1 期
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsAdvanced Solid TumorsNCT05134948Bristol-Myers Squibb24
已完成
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced CancerNCT03459222Bristol-Myers Squibb229